Cytokine variations in patients with hormone treated prostate cancer

被引:127
作者
Wise, GJ [1 ]
Marella, VK
Talluri, G
Shirazian, D
机构
[1] Maimonides Hosp, Div Urol, Brooklyn, NY 11219 USA
[2] Maimonides Hosp, Div Urol Res, Brooklyn, NY USA
关键词
prostate; prostatic neoplasms; cytokines; prostatic hyperplasia;
D O I
10.1016/S0022-5347(05)67289-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated the immunological response in patients with hormone sensitive and refractory prostate cancer, and untreated benign prostatic hyperplasia (BPH). Materials and Methods: Serum levels of pro-inflammatory and anti-inflammatory cytokines were measured by enzyme-linked immunosorbent assay in 3 groups of patients. The groups included 18 men with a mean age of 79 years who had hormone sensitive prostate cancer, mean prostate specific antigen (PSA) plus or minus standard deviation 1.03 +/- 2.65 ng./ml. and a mean of 35 months of treatment, 10 with a mean age of 86 years who had hormone refractory prostate cancer, mean PSA 27.52 +/- 42.23 ng./ml. and a mean of 42 months of treatment;, and 19 with a mean age of 73 years who had BPH and mean PSA 3.37 +/- 2.47 ng./ml. Results were compared with those in 10 age matched, disease-free controls. In the hormone sensitive group PSA regressed to normal and there was clinical evidence of a response to hormone ablation therapy, including orchiectomy, luteinizing hormone releasing hormone analogue and androgen blockade. Hormone refractory cases had elevated PSA and/or clinical evidence of disease progression. Results: Levels of the anti-inflammatory cytokines interleukin (IL)-4, IL-6 and IL-10 were significantly elevated in the hormone refractory group compared with values in the hormone sensitive group (p = 0.02, 0.01 and 0.0001, respectively). Abnormal anti-inflammatory cytokines in hormone resistant cases correlated with elevated PSA, while in the BPH group there was no significant difference from controls. Pro-inflammatory cytokines in the hormone sensitive and resistant groups were not significantly different from those in controls. Conclusions: Our study indicates that in hormone refractory prostate cancer a high level of the anti-inflammatory cytokines IL-4, IL-6 and IL-10 develops that is directly associated with elevated PSA. Changes in the level of anti-inflammatory cytokines when androgen independent cells exist may have an important role in the selection of a subset, of hormone insensitive cells. These criteria may be used as a prognostic marker for the response to hormone ablation therapy in men with prostate cancer.
引用
收藏
页码:722 / 725
页数:4
相关论文
共 17 条
[1]   Relationship between serum levels of interleukin-6, tumor necrosis factor-α and bone turnover markers in prostate cancer patients [J].
Akimoto, S ;
Okumura, A ;
Fuse, H .
ENDOCRINE JOURNAL, 1998, 45 (02) :183-189
[2]  
Diaz M, 1998, PROSTATE, P32
[3]  
DURUM SK, 1993, FUNDAMENTAL IMMUNOLO
[4]  
Huggins C, 1941, CANCER RES, V1, P293
[5]   The biology of hormone refractory prostate cancer - Why does it develop? [J].
Isaacs, JT .
UROLOGIC CLINICS OF NORTH AMERICA, 1999, 26 (02) :263-+
[6]   Cancer statistics, 1998 [J].
Landis, SH ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 1998, 48 (01) :6-+
[7]   Cellular interactions in prostate cancer [J].
Lee, C .
BRITISH JOURNAL OF UROLOGY, 1997, 79 :21-27
[8]   Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line [J].
Lévesque, E ;
Beaulieu, M ;
Guillemette, C ;
Hum, DW ;
Bélanger, A .
ENDOCRINOLOGY, 1998, 139 (05) :2375-2381
[9]   Evolution of the type-1 (Th1)-type-2 (Th2) cytokine paradigm. [J].
Lucey, DR .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1999, 13 (01) :1-+
[10]  
MOKHTARIAN F, 1994, J IMMUNOL, V152, P6003